Get the Daily Brief
Latest Biotech News
Breakthrough Gene Editing Tools Enable Megabase-Scale DNA Rearrangements
Researchers at the Arc Institute developed programmable bridge recombinases, RNA-guided enzymes capable of executing large-scale genomic rearrangements in human cells. This technology enables...
Novel Cancer Immunotherapy Targets Glycan Antigens to Spare Healthy Tissue
Scientists at UC Irvine engineered glycan-dependent T cell recruiter (GlyTR) compounds that selectively bind tumor-associated carbohydrate antigens, activating T cells to kill diverse cancer cells...
NIH Launches $87 Million Standardized Organoid Modeling Center
The National Institutes of Health announced funding for the Standardized Organoid Modeling Center (SOMC) to accelerate development and reproducibility in organoid research, allocating $87 million...
Discovery of Candida albicans Toxin Regulation Enables Persistent Oral Colonization
A team of researchers revealed that Candida albicans utilizes finely balanced production of the toxin candidalysin to establish long-term colonization in the oral mucosa while evading immune...
FDA Clears Crinetics’ Oral Pill for First-Line Acromegaly Treatment
The U.S. Food and Drug Administration has approved Crinetics Pharmaceuticals’ Palsonify (paltusotine), marking the company's first authorized product. This once-daily oral therapy targets...
Eli Lilly’s Oral SERD Inluriyo Approved for ESR1-Mutated Breast Cancer
Eli Lilly received FDA approval for Imlunestrant (Inluriyo), an oral selective estrogen receptor degrader, to treat adults with advanced or metastatic estrogen receptor-positive, HER2-negative...
Trump Administration Imposes 100% Tariffs on Imported Branded Pharmaceuticals
President Donald Trump announced a 100% tariff on imported branded pharmaceutical products effective October 1, 2025, with carve-outs for generic drugs and exemptions for companies building...
ARPA-H Launches Nine-Figure Programs to Expand Personalized Gene Editing Therapies
The Advanced Research Projects Agency for Health (ARPA-H) unveiled two multi-million-dollar initiatives, THRIVE and GIVE, aimed at accelerating development and manufacturing of custom gene editing...
Bridge Recombinase Technology Enables Megabase-Scale DNA Rearrangements in Human Cells
Researchers at the Arc Institute have engineered a novel, RNA-guided bridge recombinase platform that enables programmable large-scale genomic DNA rearrangements, including insertions, deletions,...
UCI Develops Pan-Cancer Immunotherapy Targeting Glycan Antigens With Reduced Toxicity
Scientists at the University of California, Irvine, introduced glycan-dependent T cell recruiter (GlyTR) compounds that selectively bind tumor-associated carbohydrate antigens to trigger potent...
AI Enhances Diagnostic Precision in Lung Lesions and Medical Coding
Multiple studies showcase artificial intelligence breakthroughs in healthcare diagnostics and administration. A novel machine learning model significantly improves accuracy in LungPro navigational...
Crinetics Pharmaceuticals’ Palsonify Poised to Challenge Acromegaly Market Leaders
Crinetics Pharmaceuticals, having secured FDA approval for Palsonify, an oral once-daily treatment for acromegaly, is positioned to compete with established injectable therapies from pharma giants...
Immuneering’s MEK Inhibitor Atebimetinib Shows Promising Data in Pancreatic Cancer Phase II Trial
Immuneering Corp. announced encouraging updated survival and safety outcomes from its ongoing Phase IIa trial combining oral MEK inhibitor atebimetinib with modified gemcitabine/nab-paclitaxel in...
FDA Clears Crinetics’ Palsonify: Oral Therapy for Acromegaly Sets Up Competition
Crinetics Pharmaceuticals received FDA approval for Palsonify (paltusotine), the first oral first-line therapy for adults with acromegaly, a rare hormonal disorder characterized by excessive...
Advanced Radiation Oncology Research Highlights at ASTRO 2025
Multiple institutions are presenting innovative advances in radiation oncology at the 2025 ASTRO Annual Meeting. University of California centers and others will showcase developments including...
Biocartis Advances Oncology Companion Diagnostics with FDA-Approved Idylla System
Biocartis is repositioning its Idylla system for automated sample-to-answer testing in oncology companion diagnostics. The FDA recently granted premarket approval for the Idylla CDx MSI Test,...
AI and Machine Learning Propel New Frontiers in Diagnostic and Biomedical Research
Cutting-edge AI applications are revolutionizing healthcare and biomedical research. Studies demonstrate that AI systems can autonomously prescribe therapeutics to prevent graft-versus-host...
Novel Immunotherapies Harness Glycan Targeting to Widen Cancer Treatment Scope
Researchers at University of California, Irvine, have developed glycan-dependent T cell recruiters (GlyTRs) that target tumor-associated carbohydrate antigens safely and effectively across...
Gene Editing Innovates with Programmable Bridge Recombinases for Large Genomic Rearrangements
Arc Institute scientists introduced a universal gene editing platform leveraging bridge recombinases to enable precise, megabase-scale DNA rearrangements in human cells. This technology...
NIH Commits $87M to Standardized Organoid Modeling Center, Advancing Alternatives to Animal Testing
The National Institutes of Health awarded $87 million over three years to launch the Standardized Organoid Modeling Center, aiming to accelerate the shift from animal testing towards reproducible...